.png "Senseonics Holdings Inc (AMEX: SENS)")
Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Senseonics Holdings Inc (AMEX: SENS) today and set a price target of $5. The company’s shares opened today at $3.26.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 11.1% and a 57.6% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Smith & Nephew Snats.
Currently, the analyst consensus on Senseonics Holdings Inc is Strong Buy and the average price target is $4.88, representing a 49.7% upside.
In a report issued on May 10, BTIG also maintained a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
Based on Senseonics Holdings Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.27 million. In comparison, last year the company had a GAAP net loss of $13.07 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SENS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Senseonics Holdings, Inc. is a medical technology company, which engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its products include eversense sensor, eversense smart transmitter, eversence mobile application, and eversense data management system.
